Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Triprolidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.97 |
| ▸ | LMNA | P02545 | 2/20 | 0.97 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.97 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.97 |
| ▸ | MEN1 | O00255 | 2/20 | 0.97 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.97 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.97 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.97 |
| ▸ | TSHR | P16473 | 1/20 | 0.97 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.97 |
| ▸ | THPO | P40225 | 1/20 | 0.97 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.95 |
| ▸ | GMNN | O75496 | 1/20 | 0.95 |
| ▸ | BLM | P54132 | 1/20 | 0.95 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.95 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triprolidine SCHEMBL4905 | 0.99 | KMT2A (1.00) | KMT2ALMNASLC6A4ADRA1AHRH1 | |
| Triprolidine SCHEMBL4906 | 0.99 | KMT2A (1.00) | KMT2ALMNASLC6A4ADRA1AHRH1 | |
| Triprolidine SCHEMBL29631820 | 0.99 | KMT2A (1.00) | KMT2ALMNASLC6A4ADRA1AHRH1 | |
| Triprolidine SCHEMBL3881294 | 0.99 | KMT2A (1.00) | KMT2ALMNASLC6A4ADRA1AHRH1 | |
| Triprolidine SCHEMBL42146 | 0.97 | LMNA (1.00) | KMT2ALMNASLC6A4ADRA1AHRH1 | |
| Triprolidine SCHEMBL9723510 | 0.97 | LMNA (1.00) | KMT2ALMNASLC6A4ADRA1AHRH1 | |
| Triprolidine SCHEMBL42145 | 0.97 | LMNA (1.00) | KMT2ALMNASLC6A4ADRA1AHRH1 | |
| Triprolidine SCHEMBL1140976 | 0.96 | LMNA (0.98) | KMT2ALMNASLC6A4ADRA1AHRH1 | |
| Triprolidine SCHEMBL1140974 | 0.96 | LMNA (0.98) | KMT2ALMNASLC6A4ADRA1AHRH1 | |
| Triprolidine SCHEMBL14973526 | 0.96 | KMT2A (0.95) | KMT2ALMNASLC6A4ADRA1AHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087385-A1 | APPLICATION OF GLYCYRRHIZIC ACID AND ITS BREAKDOWN PRODUCT GLYCYRRHETINIC ACID FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | ONEPHARM RESEARCH & DEVELOPMENT (AT) | 2010-04-08 | — | — | US | disclosed |
| EP-2067476-A1 | THE APPLICATION OF GLYCYRRHIZIC ACID AND ITS BREAKDOWN PRODUCT GLYCYRRHETINIC ACID FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | Wuhan University (CN) | 2009-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087385-A1 | APPLICATION OF GLYCYRRHIZIC ACID AND ITS BREAKDOWN PRODUCT GLYCYRRHETINIC ACID FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | SI, GSR, AGER | HRH1 460/4885KMT2A 4263/4885LMNA 3834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.